Bi -institutional Safety Analysis of Combining Radiotherapy and Enfortumab Vedotin in Advanced Urothelial Cancer

被引：0
|
作者：
Soni, Y. S. [1 ]
Lock, D. [2 ]
Ballas, L. K. [3 ]
Hwang, L. [2 ]
Cole, S. [4 ]
D'Souza, A. [5 ]
Zhang, T. [4 ]
Garant, A. [1 ]
Yang, D. X. [1 ]
Arafat, W. [4 ]
Desai, N. B. [1 ]
机构：
[1] Univ Texas Southwestern Med Ctr, Dept Radiat Oncol, Dallas, TX USA
[2] LAC USC Med Ctr, Dept Radiat Oncol, Los Angeles, CA USA
[3] Cedars Sinai Med Ctr, Dept Radiat Oncol, Los Angeles, CA USA
[4] Univ Texas Southwestern Med Ctr, Dept Hematol & Oncol, Dallas, TX USA
[5] LAC USC Med Ctr, Dept Hematol & Oncol, Los Angeles, CA USA
来源：
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2024年 / 120卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
222
引用
收藏
页码：S74 / S75
页数：2
相关论文
共 50 条
  • [21] A CASE OF ENFORTUMAB VEDOTIN TOXICITY IN A PATIENT WITH ADVANCED UROTHELIAL CELL CARCINOMA
    Grigsby, Charles
    Thebert, Alexander
    Pijut, Kyle
    Woodward, Blake
    Bastin, Melissa Thompson
    Soper, Melissa
    Fozzard, Andrew
    CRITICAL CARE MEDICINE, 2024, 52
  • [22] Impact of Relative Dose Intensity of Enfortumab Vedotin for Advanced Urothelial Carcinoma
    Furubayashi, Nobuki
    Negishi, Takahito
    Mochida, Manabu
    Kijima, Atsuhiro
    Katsuki, Harumichi
    Nakamura, Motonobu
    IN VIVO, 2025, 39 (01): : 411 - 418
  • [23] Real world evidence of enfortumab vedotin in patients with advanced urothelial cancer: A multicenter observational study
    Fukuokaya, Wataru
    Koike, Yuhei
    Yata, Yuji
    Komura, Kazumasa
    Uchimoto, Taizo
    Tsujino, Takuya
    Saruta, Masanobu
    Takahara, Kiyoshi
    Fujita, Kazutoshi
    Minami, Takafumi
    Adachi, Takahiro
    Hirasawa, Yosuke
    Hashimoto, Takeshi
    Ohno, Yoshio
    Uemura, Hirotsugu
    Shiroki, Ryoichi
    Azuma, Haruhito
    Kimura, Takahiro
    INTERNATIONAL JOURNAL OF UROLOGY, 2024, 31 (04) : 342 - 347
  • [24] Therapeutic efficacy and safety of biweekly administration of enfortumab vedotin for urothelial carcinoma
    Nakagawa, Ryunosuke
    Izumi, Kouji
    Toriumi, Ren
    Aoyama, Shuhei
    Kamijima, Taiki
    Kano, Hiroshi
    Makino, Tomoyuki
    Naito, Renato
    Iwamoto, Hiroaki
    Yaegashi, Hiroshi
    Kawaguchi, Shohei
    Shigehara, Kazuyoshi
    Nohara, Takahiro
    Mizokami, Atsushi
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2024, 54 (12) : 1329 - 1335
  • [25] Enfortumab vedotin - next game-changer in urothelial cancer
    Maas, Moritz
    Stuehler, Viktoria
    Walz, Simon
    Stenzl, Arnulf
    Bedke, Jens
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2021, 21 (07) : 801 - 809
  • [26] Enfortumab vedotin for cisplatin-ineligible urothelial cancer Comment
    Pignot, Geraldine
    LANCET ONCOLOGY, 2021, 22 (06): : 748 - 749
  • [27] Increased risk of hyperglycemia in patients with advanced urothelial cancer treated with enfortumab vedotin: A systematic review and meta-analysis
    Cheng, Ryan
    Boparai, Montek
    Wu, Shenhong
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [28] Clinical Overview of Enfortumab Vedotin in the Management of Locally Advanced or Metastatic Urothelial Carcinoma
    Hanna, Kirollos S.
    DRUGS, 2020, 80 (01) : 1 - 7
  • [29] Cost-effectiveness of enfortumab vedotin in previously treated advanced urothelial carcinoma
    Wu, Qiuji
    Qin, Yi
    Liao, Weiting
    Zhang, Mengxi
    Yang, Yang
    Zhang, Pengfei
    Li, Qiu
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2022, 14
  • [30] Cutaneous and Renal Toxicities of Enfortumab Vedotin for Advanced Urothelial Carcinoma: The UROKYU Study
    Furubayashi, Nobuki
    Minato, Akinori
    Tomoda, Toshihisa
    Masaoka, Hiroyuki
    Hori, Yoshifumi
    Kiyoshima, Keijiro
    Negishi, Takahito
    Haraguchi, Yusuke
    Koga, Toshiki
    Song, Yoohyun
    Harada, Kenichi
    ANTICANCER RESEARCH, 2024, 44 (07) : 3025 - 3032
12345